Bench-to-bedside review: the effects of hyperoxia during critical illness by Hendrik J. F. Helmerhorst et al.
Helmerhorst et al. Critical Care  (2015) 19:284 
DOI 10.1186/s13054-015-0996-4REVIEW Open AccessBench-to-bedside review: the effects of
hyperoxia during critical illness
Hendrik J. F. Helmerhorst1,2*, Marcus J. Schultz2,3, Peter H. J. van der Voort4,5, Evert de Jonge1
and David J. van Westerloo1Abstract
Oxygen administration is uniformly used in emergency
and intensive care medicine and has life-saving potential
in critical conditions. However, excessive oxygenation
also has deleterious properties in various
pathophysiological processes and consequently both
clinical and translational studies investigating hyperoxia
during critical illness have gained increasing interest.
Reactive oxygen species are notorious by-products of
hyperoxia and play a pivotal role in cell signaling
pathways. The effects are diverse, but when the
homeostatic balance is disturbed, reactive oxygen
species typically conserve a vicious cycle of tissue injury,
characterized by cell damage, cell death, and
inflammation. The most prominent symptoms in the
abundantly exposed lungs include tracheobronchitis,
pulmonary edema, and respiratory failure. In addition,
absorptive atelectasis results as a physiological
phenomenon with increasing levels of inspiratory
oxygen. Hyperoxia-induced vasoconstriction can be
beneficial during vasodilatory shock, but hemodynamic
changes may also impose risk when organ perfusion is
impaired. In this context, oxygen may be recognized as
a multifaceted agent, a modifiable risk factor, and a
feasible target for intervention. Although most clinical
outcomes are still under extensive investigation, careful
titration of oxygen supply is warranted in order to
secure adequate tissue oxygenation while preventing
hyperoxic harm.Pathogenesis from the benchside
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Oxygen is a vital element in human survival and plays a
major role in a diverse range of biological and physio-
logical processes. In medical practice, it is among the
most universally used agents for the treatment of critical
illness [1] and part of the routine treatment in acute
shock and emergency medicine [2]. To ensure sufficient
oxygenation, oxygen therapy during mechanical ventila-
tion, anesthesia, and resuscitation usually exceeds physio-
logical levels. However, Renaissance physician Paracelsus
noted: “nothing is without poison—the poison is in the
dose”. This accounts for many aspects in medicine but
may also be applicable to the oxygen molecule [3]. The
concept of oxygen toxicity was described in the late 19th
century following the pioneering efforts of James Lorrain
Smith and Paul Bert, but it was not until a century later
that the effects of hyperoxia were increasingly studied. Al-
though several lines of evidence indicate that hyperoxia
may be harmful, robust interventional studies are still lim-
ited. To develop adequate recommendations for optimal
oxygen levels, it is important to extend our current under-
standings of hyperoxia-induced injury. The aim of this re-
view is to provide a comprehensive overview of the effects
of hyperoxia from the bench and the bedside. The first
part will focus on established insights and recent experi-
mental and translational advances; the latter part ad-
dresses pathophysiological concepts, clinical studies, and
implications for therapy.Reactive oxygen species (ROS) are versatile molecules
that can be essential in the regulation of intracellular sig-
naling pathways and in host defense [4]. However, ROS
have also repeatedly been postulated to be of major sig-
nificance in tissue damage, organ dysfunction, and clin-
ical disease. In regard to oxygen toxicity, it is frequently
assumed that it is not oxygen itself that exerts toxic effects
but merely the ROS that are generated as an undesirableess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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aerobic cellular metabolism. The implications for the
lungs are probably the most prominent as lung tissue is
continuously and abundantly exposed to oxygen and its
by-products. In physiological circumstances, ROS are
formed in the electron transport chain during proton
transport across the inner mitochondrial membrane.
Mitochondrial oxidative phosphorylation is the most im-
portant source of oxygen species, but ROS may also be
generated in response to exogenous stimuli, such as mi-
crobes, cytokines, and xenobiotics [5]. Antioxidant tasks
are accomplished by enzymes as catalases, glutathione
peroxidases, thioredoxins, and peroxyredoxins. These en-
zymes use electron donors in order to avoid the inter-
mediate formation of the hydroxyl radical (OH∙), which is
a strongly reactive oxidant. In this process, superoxide dis-
mutase is an important antioxidant enzyme as it efficiently
reduces the concentration of the superoxide anion (O2∙
–)
by facilitating its rapid conversion in hydrogen peroxide
(H2O2) or oxygen (O2). In general, ROS generation from
mitochondria increases with oxygen tension and is de-
pendent on the clinical balance between the underlying
condition and oxygen supply [6]. In response to bacterial
invasion, neutrophils can also produce large amounts of
ROS that may initially be beneficial in the host defense
against several pathogens. Fortunately, the lungs are prin-
cipally well protected against oxygen toxicity by adequate
intra—and extracellular antioxidant activity. Besides this
physiological activity, additional antioxidants can be re-
cruited in the epithelial lining fluid [7]. However, when
the production of ROS exceeds the limits of counteraction
by antioxidant responses, ROS concentrations reach inad-
equate levels and a cellular state of oxidative stress mani-
fests. Oxidative stress refers to the imbalance caused by
increased ROS formation or deficient oxidant suppressors
[8]. When antioxidant systems are insufficient during crit-
ical illness and mechanical ventilation, supplemental oxy-
gen can cause accumulation of oxygen radicals and may
initiate or perpetuate oxygen toxicity. Moreover, ROS con-
trol can be markedly influenced by aging, genetic factors,
and pharmacochemical agents [6].
Cell death
When the delicate homeostatic balance is disturbed, oxi-
dative stress leads to damage of nucleic acids, proteins,
and lipids, resulting in cell death by both apoptotic and
necrotic pathways [9]. Necrosis is characterized by in-
complete apoptosis and supported by integrity loss of
the cell membrane and cytoplasmic swelling. Programmed
cell death by apoptosis can be achieved through extrinsic
or intrinsic pathways, concomitantly. The extrinsic path-
way is triggered by extracellular signals that stimulate
intracellular apoptotic cascades after binding the cell
membrane. The intrinsic apoptotic pathway is initiated byincreased mitochondrial ROS formation. Subsequently,
the opening of transition pores is facilitated, making the
outer mitochondrial membrane more permeable for pro-
apoptotic components. These components can then pass
to the cytoplasm and induce a state of intracellular stress.
When this occurs in both endothelial and epithelial cells,
lytic damage and cell death contribute to interstitial pul-
monary edema and impaired gas exchange by means of al-
veolar collapse and disintegration of the alveolar-capillary
barrier.
Cell damage and inflammatory pathways
In addition to direct cell death by necrosis or apoptosis,
cellular disruption caused by hyperoxia and ROS has
been shown to release endogenous damage-associated
molecular pattern molecules (DAMPs) that alert the in-
nate immune system [10–12]. DAMPs, or alarmins, are
cell fragments released during cellular dysfunction and
sterile injury and act as pleiotropic modulators of in-
flammation. During oxidative stress, mitochondrial dam-
age is a pivotal cause of extracellular hazardous content
including both free radicals and DAMPs. Because they
resemble bacterial DNA, circulating mitochondrial DAMPs
are efficiently recognized by pattern recognition receptors
and activate polymorphonuclear neutrophils (PMNs). Sub-
sequently, PMNs release interleukins and contribute to a
sterile inflammatory reaction and, ultimately, neutrophil-
mediated organ injury. In response to hyperoxia-mediated
ROS production, resident lung cells initiate the release
of various cytokines. Chemotactic factors orchestrate the
inflammatory response by attracting inflammatory cells
to the pulmonary compartment. Recruited neutrophils
and monocytes, in turn, are significant sources of add-
itional ROS, conserving a vicious cycle leading to further
tissue damage (Fig. 1). Under enduring conditions of in-
jury to pulmonary epithelium and increasing alveolar
permeability, cytokines can translocate from the alveolar
space to the systemic circulation, creating a systemic in-
flammatory response, in which cytokines are efficiently
activated and phagocytosis by alveolar macrophages is
hampered [13]. Cytokine concentrations decrease after
long-term exposure, suggesting that a fast upregulation
of inflammatory action is followed by a gradual impair-
ment of the innate immune system [14]. Besides mito-
chondrial damage, the inflammatory actions of oxygen
are importantly modulated by hypoxia-inducible factor
(HIF) [15, 16]. HIF-1α is thought to be upregulated dur-
ing relative changes in oxygenation and accordingly re-
sponds to normoxia as a relative hypoxic state directly
after hyperoxia. Through this mechanism, intermittent
hyperoxia may trigger a paradoxical phenomenon in
which the genetic expression of inflammatory mediators
and erythropoietin is stimulated in the absence of true
tissue hypoxia [17].
Fig. 1 (See legend on next page.)
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Fig. 1 Vicious cycle of hyperoxia-induced cell injury. AP activator protein, DAMP damage-associated molecular pattern molecules, H2O2 hydrogen
peroxide, IFN interferon gamma, IL interleukin, MAPK mitogen-activated protein kinase, NADPH nicotinamide adenine dinucleotide phosphate,
NF-κB nuclear factor kappa B, NLR nod-like receptor, Nrf2 nuclear factor-2 erythroid related factor-2, O2 oxygen, O2
·−superoxide, OH· hydroxyl radical,
ONOO− peroxynitrite, PMN polymorphonuclear neutrophil, RAGE receptor for advanced glycation end products, ROS reactive oxygen species, TLR Toll-
like receptor, TNF tumor necrosis factor, VEGF vascular endothelial growth factor
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Principal insights in hyperoxia-induced mechanisms
have been obtained from experimental models. The first
animal studies documented structural morphologic and
biochemical changes in the lungs of a wide variety of
animal species that were exposed to hyperoxia [18]. Pio-
neering studies using conscious dogs postulated that
normobaric hyperoxia decreased metabolic rate and
altered hemodynamics [19, 20]. These findings were
reproduced in primates in which progressive pulmonary
injury, interstitial edema, and inflammatory activation
were observed [21]. In later experiments, biochemical ef-
fects of ROS and interventional targets on the molecular
level were more intensively studied in spontaneously
breathing animals in hyperoxic environments and showed
both detrimental and protective potential [22–26]. Recent
experiments were performed in mechanically ventilated
rodents, rabbits, and pigs, mimicking the clinical environ-
ment of critically ill patients [27–31]. In this context, the
interaction between injurious ventilation and concurrent
hyperoxia was shown to transcend lung injury by alveolar
distention alone [22, 32–35]. However, studies in mechan-
ically ventilated animals are usually restricted to short ex-
posure periods [32, 34–38], even though hyperoxia may
induce time-dependent inflammation [23]. To improve
our understanding of the impact of long-term exposure to
both mechanical ventilation and hyperoxia, future studies
involving mechanical ventilation of longer duration and
with clinically relevant settings are essential for a robust
representation of the ICU environment.
Pathogenesis from the bedside
Hyperoxia-induced tissue injury
Under normobaric circumstances, the side effects of oxy-
gen are initially restricted to the lungs. However, when
hyperoxia manifests for prolonged periods or under
hyperbaric conditions, other organs are concurrently at
risk as more oxygen is dissolved in plasma [6]. The
amount of dissolved oxygen will readily increase at partial
pressures of arterial oxygen (PaO2) exceeding 100 mm
Hg. Oxyhemoglobin saturation is nearly complete when
PaO2 approaches this level and the carrying capacity of
hemoglobin is therefore quickly overcharged with increas-
ing fractions of inspired oxygen (FiO2).
The harmful effects depend on underlying conditions,
duration, and degree of the hyperoxic exposure. Rigid
thresholds where harm exceeds the perceived benefitsare not exactly known and may vary between subgroups
[39]. Most pathophysiological changes originate rapidly
and are rather universal effects, but the effects of hyper-
oxia are assumed to be time—and dose-dependent [40].
In general, excessive oxygen supply causes absorptive
atelectasis by displacement of alveolar nitrogen. The
progressive washout of nitrogen coincides with the
abundant presence of oxygen in the alveoli which, driven
by a steep pressure gradient, rapidly diffuses into the
mixed venous blood. As a result, the alveolar volume is
markedly reduced and leads to increased ventilation/per-
fusion mismatch by (partial) alveolar collapse and im-
paired gas exchange, which can be attenuated by applying
positive end-expiratory pressure [41]. Impaired mucocili-
ary clearance by hyperoxia contributes to obstructive
atelectasis, and altered surfactant metabolism facilitates
adhesive atelectasis through alveolar instability and col-
lapse. Several lines of evidence indicate further effects of
breathing high oxygen levels in animals and healthy sub-
jects [1, 42], but evidence of pulmonary toxicity in a clin-
ical scenario is limited [43]. The pathological features of
this condition are commonly referred to as the Lorrain
Smith effect [44] and are characterized by tracheobronchi-
tis, which can be accompanied by pleuritic pain, bronchial
irritation, cough, and sore throat. Symptoms may spread
from the upper airways into the lungs, where diffuse al-
veolar damage manifests and contributes to edema, vascu-
lar leakage, arteriolar thickening, pulmonary fibrosis, and
emphysema, reflected by progressive paradoxical hypoxia,
dyspnea, and tachypnea. Additionally, prolonged hyper-
oxic exposure alters the microbial flora in the upper air-
ways and further increases the risk of secondary infections
and lethality. Notably, these pulmonary effects are often in
addition to the primary (e.g., pneumonia) and secondary
(e.g., ventilator-induced lung injury) lung injury, which are
accompanied by inflammatory responses.
The central nervous system is typically the first to suf-
fer from the effects of excessive ROS formation. The
spectrum of neurological symptoms is referred to as the
Paul Bert effect and ranges from nausea, dizziness, and
headache to vision disturbances (retinal damage), neu-
ropathies, paralysis, and convulsions [1].
Vascular effects of hyperoxia have been well docu-
mented and may have both harmful and beneficial ef-
fects. Arterial hyperoxia increases the systemic vascular
resistance and induces vasoconstriction, which may impair
organ perfusion, especially in the cerebral and coronary
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result from even short-term exposure and include a de-
crease in heart rate, stroke volume, and cardiac output
[48]. However, hyperoxia is not a universal vasocon-
strictor in all vascular regions, and blood flow may be
redistributed to the hepatosplanchnic circulation in septic
shock [1, 49]. Alternatively, the administration of oxygen
promotes hemodynamic stabilization during vasodilatory
shock, decreases intracranial pressure by cerebral vaso-




Recent studies assessing the clinical effects of arterial
hyperoxia or normobaric supplemental oxygen in critical
care are listed in Table 1. As highlighted in recent meta-
analyses [51, 52], the effects on major clinical endpoints
are conflicting and may be partially explained by heteroge-
neous methodology and subgroup differences in critically
ill patients. Pooled effect estimates favoring normoxia are
quite consistent, but the harmful effects were previously
shown to be impacted by the definition of hyperoxia and
may be more pertinent to specific subgroups and at spe-
cific moments of admission.
It is well established that the use of higher FiO2 can
lead to progressive hypercapnia during a state of chronic
compensated respiratory acidosis, and serious adverse
outcomes have been shown in acute exacerbations of
chronic obstructive pulmonary disease or asthma [53–55].
Likewise, high fractions of oxygen in the inspired air and
arterial blood have been associated with increased mortal-
ity in mechanically ventilated patients [56].
Owing to a striking lack of robust clinical trials, a
causal relationship is still uncertain and both the magni-
tude and direction of the associations depend on the
adjustment for illness severity scores, FiO2, and other
confounders [56, 57]. Future randomized controlled
studies are urgently needed to definitively elucidate the
causal effects of oxygenation targets and derangements
on clinical outcomes of critically ill patients.
Excessive oxygenation may be most intensively studied
after resuscitation from cardiac arrest as both the vascular
alterations and the ischemia and reperfusion injury are hy-
pothesized to be hazardous [58]. In a dose-dependent
manner, hyperoxia has been linked to worse outcome in
these patients [59–62]. The adverse association was not
systematically reproduced and this was possibly due to
heterogeneity in study methods [63–68]. The only ran-
domized controlled trial in the post-resuscitation period
found that 30 % oxygen ventilation was not worse in com-
parison with 100 % oxygen, but the study was underpow-
ered to detect significant differences [69]. In view of all
recent data, supplemental oxygen administration duringresuscitation still appears desirable, but hyperoxia should
be avoided in the post-resuscitation phase and saturation
should be targeted at 94–96 % [58, 70].
A large number of both experimental and clinical
studies have primed pediatricians with great awareness
of the risks of hyperoxia. For neonatal resuscitation, the
routine use of 100 % oxygen has been abandoned after
numerous associations with myocardial, neurological,
and kidney injury and retinopathy, inflammation, and in-
creased mortality [71, 72]. However, strict adherence to
lower target ranges of oxygen saturation among preterm
infants did not significantly reduce disability or deaths
[73]. Results from a prospective large-scale meta-analysis
investigating the most appropriate level of oxygenation
for extremely preterm neonates suggested that func-
tional oxyhemoglobin saturation be targeted at 90–95 %
in the post-natal period [74].
Hyperoxia-induced vasoconstriction poses a major con-
cern in the management of acute coronary syndromes,
and guidelines increasingly suggest a restriction of supple-
mentary oxygen to only those at increased risk for hypoxia
[75]. Indeed, oxygen therapy has not been shown to be
beneficial after acute myocardial infarction and may even
be harmful, causing a marked reduction in coronary blood
flow and myocardial oxygen consumption [76, 77]. The
vasoconstriction caused by hyperoxia may be of special
concern in the acute setting before reperfusion. The
AVOID (Air Verses Oxygen In myocarDial infarction) trial
aimed to definitively qualify the role of supplemental oxy-
gen in acute myocardial infarction [78] and found
increased myocardial injury, recurrent myocardial infarc-
tion, cardiac arrhythmia, and infarct size at 6 months [79].
In contrast, a smaller trial observed a beneficial effect of
30–40 % oxygen inhalation over controls during both oc-
clusion and reperfusion [80]. Hemodynamic effects may
also be pertinent to acute ischemic stroke patients, who
do not appear to benefit from increased survival after pro-
longed treatment with oxygen [81, 82].
Despite the theoretical benefit of decreasing intracranial
pressure through cerebral vasoconstriction, hyperoxia has
repeatedly been associated with delayed cerebral ischemia
and increased cerebral excitotoxicity after cerebrovascular
incidents [83–85]. Interestingly, the synergistic combin-
ation of hyperbaric and normobaric hyperoxia was re-
cently found to have potential therapeutic efficacy in
severe traumatic brain injury [86]. However, observational
data in patients with traumatic brain injury, ischemic
stroke, subarachnoid, or intracerebral hemorrhage remain
equivocal [87–92].
Perioperative care
Liberal oxygen supply is usually accepted in periopera-
tive care in order to avoid potentially life-threatening
consequences of hypoxia during surgery. Further effects
Table 1 Studies assessing the clinical effects of arterial hyperoxia or supplemental oxygen in subgroups of critically ill patients
Author Country Study type Inclusion period Subgroup Sample size Harm Conclusions
Eastwood et al. [57] (2012) Australia and
New Zealand
Cohort 2000–2009 MV 152,680 – Hypoxia in first 24 h of admission was associated with increased
in-hospital mortality, but hyperoxia was not.
de Jonge et al. [56] (2008) The Netherlands Cohort 1999–2006 MV 36,307 + High FiO2 and both low PaO2 and high PaO2 in first 24 h of
admission were associated with in-hospital mortality
Suzuki et al. [96] (2014) Australia Before-after pilot 2012 MV 105 +/– Conservative oxygen therapy in mechanically ventilated ICU
patients was feasible and free of adverse biochemical,
physiological, or clinical outcomes while allowing a marked
decrease in excess oxygen exposure
Aboab et al. [41] (2006) France Experimental NA ARDS 14 +/– In mechanically ventilated patients with ARDS, the breathing
of pure oxygen leads to alveolar derecruitment, which is
prevented by high PEEP
Austin et al. [53] (2010) Australia RCT 2006–2007 COPD 405 + Titrated oxygen treatment significantly reduced mortality,
hypercapnia, and respiratory acidosis compared with
high-flow oxygen in acute exacerbations of COPD
Cameron et al. [55] (2012) New Zealand Cohort 2005–2008 COPD 180 + Serious adverse clinical outcomes are associated with both
hypoxaemia and hyperoxaemia during acute exacerbations
Perrin et al. [54] (2011) New Zealand RCT 2007–2009 Asthma 106 + High-concentration oxygen therapy causes a clinically
significant increase in transcutaneous CO2 during
severe exacerbations
Bellomo et al. [63] (2011) Australia and
New Zealand
Cohort 2000–2009 CA 12,108 – Hyperoxia did not have a robust or consistently reproducible
association with mortality
Elmer et al. [62] (2014) USA Cohort 2008–2010 CA 184 + Severe hyperoxia was independently associated with
decreased survival to hospital discharge
Ihle et al. [64] (2013) Australia Cohort 2007–2011 CA 584 – Hyperoxia within the first 24 h was not associated with
increased hospital mortality
Janz et al. [61] (2012) USA Cohort 2007–2012 CA 170 + Higher levels of the maximum measured PaO2 were
associated with increased in-hospital mortality and
poor neurological status on hospital discharge
Kilgannon et al. [59] (2010) USA Cohort 2001–2005 CA 6326 + Arterial hyperoxia was independently associated with
increased in-hospital mortality compared with either
hypoxia or normoxia
Kilgannon et al. [60] (2011) USA Cohort substudy 2001–2005 CA 4459 + Supranormal oxygen tension was dose-dependently
associated with the risk of in-hospital death
Kuisma et al. [69] (2006) Finland RCT pilot NA CA 28 – No indication that 30 % oxygen with SpO2 monitoring
did worse than the group receiving 100 % oxygen
Lee et al. [65] (2014) Korea Cohort 2008–2012 CA 213 – Mean PaO2 was not independently associated with
in-hospital mortality
Nelskyla et al. [112] (2013) Australia Cohort 2008–2010 CA 122 – No statistically significant differences in numbers of
patients discharged from the hospital and 30-day survival
between patients with hyperoxia exposure and no exposure
Spindelboeck et al. [67] (2013) Austria Cohort 2003–2010 CA 145 – Increasing PaO2 was associated with a significantly increased











Table 1 Studies assessing the clinical effects of arterial hyperoxia or supplemental oxygen in subgroups of critically ill patients (Continued)
Vaahersalo et al. [66] (2014) Finland Cohort 2010–2011 CA 409 – Hypercapnia was associated with good 12-month outcome,
but harm from hyperoxia exposure was not verified
Minana et al. [113] (2011) Spain Cohort 2003–2009 ADHF 588 – Admission PaO2 was not associated with all-cause
long-term mortality
Ranchord et al. [114] (2012) New Zealand RCT pilot 2007–2009 STEMI 136 – No evidence of benefit or harm from high-concentration
compared with titrated oxygen
Stub et al. [78] (2012) Australia RCT 2011–2014 STEMI 441 + Supplemental oxygen therapy in patients with STEMI but
without hypoxia increased myocardial injury, recurrent
myocardial infarction, and cardiac arrhythmia and was
associated with larger myocardial infarct size at 6 months.
Further results anticipated.
Sutton et al. [115] (2014) Australia and
New Zealand
Cohort 2003–2012 Post cardiac
surgery
83,060 – No association between mortality and hyperoxia in the
first 24 h in ICU after cardiac surgery
Ukholkina et al. [80] (2005) Russia RCT NA AMI 137 – Inhalation of 30–40 % oxygen within 30 min prior to
endovascular myocardial reperfusion and within 4 h
thereafter reduced the area of necrosis and peri-infarction
area, improved central hemodynamics, and decreased the
rate of post-operative rhythm disorders as compared with
patients breathing ambient air
Zughaft et al. [116] (2013) Sweden RCT NA ACS 300 – The use of oxygen during PCI did not demonstrate any
analgesic effect and no difference in myocardial injury
measured with troponin- t or in the morphine dose
Asher et al. [89] (2013) USA Cohort NA TBI 193 – PaO2 threshold between 250 and 486 mm Hg during the
first 72 h after injury was associated with improved all-cause
survival independently of hypocarbia or hypercarbia
Brenner et al. [88] (2012) USA Cohort 2002–2007 TBI 1547 + Hyperoxia within the first 24 h of hospitalization was
associated with worse short-term functional outcomes
and higher mortality
Davis et al. [87] (2009) USA Cohort 1987–2003 TBI 3420 + Both hypoxemia and extreme hyperoxemia were associated
with increased mortality and a decrease in good outcomes
Quintard et al. [83] (2014) Switzerland Cohort 2009–2013 TBI 36 + Incremental normobaric FiO2 levels were associated with
increased cerebral excitotoxicity independently from brain
tissue oxygen and other important cerebral and
systemic determinants
Raj et al. [90] (2013) Finland Cohort 2003–2012 TBI 1116 – Hyperoxemia in the first 24 h of admission was not predictive
of 6-month mortality
Rincon et al. [92] (2013) USA Cohort 2003–2008 TBI 1212 + Arterial hyperoxia was independently associated with higher
in-hospital case fatality
Jeon et al. [84] (2014) USA Cohort 1996–2011 Stroke 252 + Exposure to hyperoxia was associated with delayed
cerebral ischemia
Rincon et al. [85] (2014) USA Cohort 2003–2008 Stroke 2894 + Arterial hyperoxia was independently associated with












Table 1 Studies assessing the clinical effects of arterial hyperoxia or supplemental oxygen in subgroups of critically ill patients (Continued)
Ali et al. [82] (2014) and
Roffe et al. [117] (2011)
UK RCT pilot 2004–2008 Stroke 289 – Routine oxygen supplementation started within 24 h of
hospital admission with acute stroke led to a small
improvement in neurological recovery at 1 week, but no
outcome differences were observed at 6 months
Ronning et al. [81] (1999) Norway Quasi-RCT 1994–1995 Stroke 310 + Supplemental oxygen should not routinely be given to
non-hypoxic patients with minor or moderate strokes
Singhal et al. [118] (2005) USA RCT pilot NA Stroke 16 – High-flow oxygen therapy is associated with a transient
improvement of clinical deficits and MRI abnormalities
Young et al. [91] (2012) Australia and
New Zealand
Cohort 2000–2009 Stroke 2643 – Worst arterial oxygen tension in the first 24 h was not
associated with outcome
Stolmeijer et al. [119] (2014) The Netherlands Cohort NA Sepsis 83 – No association between mortality and hyperoxia, nor
between lower FiO2 and other detrimental effects
NA, not available; +, study found harm from supplemental oxygen or arterial hyperoxia; –, no harm found from supplemental oxygen or arterial hyperoxia
ACS Acute coronary syndrome, ADHF Acute decompensated heart failure, AMI Acute myocardial infarction, ARDS Acute respiratory distress syndrome, CA Cardiac arrest, CO2 Carbon dioxide, COPD Chronic obstructive
pulmonary disease, FiO2 Fraction of inspired oxygen, ICU Intensive care unit, MRI Magnetic resonance imaging, PaO2 Partial pressure of arterial oxygen, PCI Percutaneous coronary intervention, MV Mechanical
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summarized in meta-analyses enrolling over 7000 pa-
tients and generally showed a reduced risk of surgical
site infections and postoperative nausea without luxation
of postoperative atelectasis [93, 94]. However, risks may
outweigh benefits in specific age groups [39] and differ-
ent subsets. This was recently highlighted in patients
undergoing cancer surgery in whom 80 % oxygen supply
in the perioperative setting showed a significantly in-
creased long-term all-cause mortality compared with
those randomly assigned to 30 % [95].
Implications for therapy
Several therapeutic options that limit the harmful effects
of hyperoxia can be contemplated, but prevention of ex-
cessive oxygenation is likely to be the most effective
strategy. A rational approach may be a more conserva-
tive administration strategy in which oxygen is titrated
to a lower tolerable level in order to prevent iatrogenic
harm while preserving adequate tissue oxygenation. Re-
cently, a pilot interventional study showed that conser-
vative oxygen therapy in mechanically ventilated patients
in the ICU can be feasible and free of adverse outcomes
while decreasing excess oxygen exposure [96]. Import-
antly, when the risks for severe tissue hypoxia are pro-
nounced, ample oxygen supply remains vital and should
be started immediately to increase oxygen delivery and
preserve tissue oxygenation. Also, oxygen may aid hemo-
dynamic stabilization and decrease intracranial pressure
and can be used to stimulate erythropoietin and increase
hemoglobin when intermittent hyperoxia is used as a
paradoxical trigger for HIF expression.
Experimental interventions to decrease harm from
hyperoxia are targeted at numerous steps in the pathway
of ROS-induced damage. The primary source for inter-
vention in the oxidative cycle is inhibition of oxidant
generation, either quantitatively or qualitatively. Bleo-
mycin and amiodarone are well-known originators of
drug-induced pulmonary disease and should be avoided
to minimize preventable ROS formation [97, 98]. Limit-
ing the exposure to other exogenous stimuli or prevent-
ing electron leakage in the electron transport chain may
protect the mitochondria, but this strategy proves cum-
bersome in actual practice. Although the clinical applic-
ability has been questioned because of little or no
preventative or therapeutic effect, the supply of antioxi-
dant enzymes may be a feasible approach to facilitate the
conversion, avoid the intermediate formation, and reduce
the concentration of strongly reactive oxidants. However,
some of these antioxidants may actually have pro-oxidant
properties, depending on their concentration and inter-
action with other molecules. The neutralizing effect of
antioxidants may not be sufficient to secure metabolic sta-
bility, even when secondary inflammation is mitigated.Finally, oxidant scavenging can shift the balance toward
harm when the role of oxidants in cell signaling pathways
is suppressed [99].
As an alternative, pathways of cell integrity, cell death,
and inflammation may be targeted to reduce further
damage and enhance the defense against oxygen radicals.
Experimental research suggests protective effects through
modulation of protein kinases [100, 101] and transcription
factors [102–105]. Moreover, numerous preclinical studies
have demonstrated that manipulation of chemokines, cyto-
kines [13, 106], growth factors [107], receptors [108–110],
and DAMPs [11, 12, 111] may limit hyperoxia-induced in-
jury, but these targets all remain to be evaluated at the
bedside.
Conclusions
Although oxygen remains of life-saving importance in
critical care, accumulating evidence has demonstrated
the prominent role of hyperoxia and the consequent
formation of ROS in the pathogenesis of several life-
threatening diseases. The toxic effects of supraphysiolo-
gical oxygen concentrations are driven by cell damage,
cell death, and inflammation. These aspects are of spe-
cial concern in the pulmonary compartment, where ab-
sorptive atelectasis impairs respiratory function at high
inspiratory oxygen levels. The cerebral and coronary cir-
culations are at specific risk when vascular alterations
manifest. Long-term exposure to hyperoxia impairs the
innate immune response and increases susceptibility to
infectious complications and tissue injury. Given that
critically ill patients are prone to inflammation, cardiovas-
cular instability, and depleted antioxidant mechanisms,
the most rational practice may be to supply oxygen con-
servatively and titrate the therapy carefully to the patient’s
needs. However, our understanding of oxygen toxicity is
limited in humans, and conflicting findings hamper the
constitution of compelling guidelines. Further research is
warranted to study hyperoxia-induced effects in clinical
practice, to elucidate time—and dose-response relation-
ships, and to provide evidence-based oxygenation targets
and interventions through robust clinical trials.
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